Cargando…
Systems pharmacology modeling of drug‐induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters
Elevations in serum bilirubin during drug treatment may indicate global liver dysfunction and a high risk of liver failure. However, drugs also can increase serum bilirubin in the absence of hepatic injury by inhibiting specific enzymes/transporters. We constructed a mechanistic model of bilirubin d...
Autores principales: | Yang, K, Battista, C, Woodhead, JL, Stahl, SH, Mettetal, JT, Watkins, PB, Siler, SQ, Howell, BA |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367379/ https://www.ncbi.nlm.nih.gov/pubmed/28074467 http://dx.doi.org/10.1002/cpt.619 |
Ejemplares similares
-
Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug‐Induced Liver Injury
por: Longo, DM, et al.
Publicado: (2016) -
Using Quantitative Systems Toxicology to Investigate Observed Species Differences in CKA-Mediated Hepatotoxicity
por: Battista, Christina, et al.
Publicado: (2018) -
Comparing the Liver Safety Profiles of 4 Next-Generation CGRP Receptor Antagonists to the Hepatotoxic CGRP Inhibitor Telcagepant Using Quantitative Systems Toxicology Modeling
por: Woodhead, Jeffrey L, et al.
Publicado: (2022) -
Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid-Mediated Troglitazone Hepatotoxicity
por: Yang, Kyunghee, et al.
Publicado: (2014) -
Modeling Drug- and Chemical-Induced Hepatotoxicity with Systems Biology Approaches
por: Bhattacharya, Sudin, et al.
Publicado: (2012)